Eli Lilly pushed retatrutide toward regulatory review after delivering additional Phase 3 obesity wins and shared results on primary endpoints. The company said it plans to file with the FDA early next year, positioning retatrutide as its next major obesity-to-cardio claim. While the new data showed strong weight-loss effects, the cardiovascular risk reduction signal was less clear than investors had hoped. Analysts will be watching how Lilly reframes the benefit-risk balance and what endpoints regulators may prioritize when evaluating retatrutide’s next submission. The update lands as the obesity drug market intensifies competition across GLP-1 and next-generation “triple agonist” mechanisms, with retatrutide still viewed as a potential step-change on efficacy—if durability and safety hold across broader populations.